"
Team:MIT
From 2014.igem.org
| Line 34: | Line 34: | ||
</table> | </table> | ||
| - | <table width= | + | <table width=90% align=center> |
| - | <tr><td><p align=left>Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery.</p></td></tr> | + | <tr><td><br><p align=left>Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery.</p></td></tr> |
<tr><td><br><h3 style="font-size:35px" align=center><u>DETECTION → TREATMENT → DELIVERY</u></h3></td></tr> | <tr><td><br><h3 style="font-size:35px" align=center><u>DETECTION → TREATMENT → DELIVERY</u></h3></td></tr> | ||
<tr><td><br></td></tr> | <tr><td><br></td></tr> | ||
Revision as of 21:12, 16 October 2014
| Home |  Our Project
|
Lab Work
|
Outreach
|
About Us
|
Medals |
Improving the Diagnosis and Treatment of | ||
ALZHEIMER'S DISEASE | ||
 |
 |
 |
Neurodegenerative disease |
Sixth leading cause of death in the US |
Current diagnostics and therapeutics |
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery. |
DETECTION → TREATMENT → DELIVERY |
DETECTION |
||
 Native beta-amyloid receptor |
 Engineered B-cell receptor |
 miRNA sensors for Alzheimer’s state |
TREATMENT |
DELIVERY |
 |
 |
Regulating beta-amyloid production |
Delivering our circuit |
